CENTOGENE to Participate in Upcoming Partnering Conferences

0
68


CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the commercial-stage important biodata life science associate for uncommon and neurodegenerative illnesses, in the present day introduced its partnering convention schedule for October 2022. Company administration and the business improvement staff shall be attending occasions in the U.Ok. and Germany. CENTOGENE invitations companions to schedule one-on-one conferences.

Please see further particulars beneath:

European Society of Gene & Cell Therapy (ESGCT) Annual Congress
  Dates: October 11-14, 2022
  Location: Edinburgh International Conference Centre (EICC), U.Ok.
  Format: One-on-one conferences
     
  To be taught extra in regards to the ESGCT Annual Congress, please go to the occasion web site (https://www.esgctcongress.com/). To arrange a one-on-one assembly with the CENTOGENE staff, contact BD@centogene.com.
     
BIO-Europe®
  Dates: October 24-26, 2022
  Location: Leipzig Messe, Germany / Virtual
  Format: Presentation, one-on-one conferences
  Presentation: CENTOGENE Digital Company Presentation
  Speaker: Kim Stratton, CENTOGENE CEO
     
  For details about BIO-Europe, please go to the occasion web site (https://informaconnect.com/bioeurope/). Book an in-person or digital assembly immediately with CENTOGENE in advance by contacting BD@centogene.com, or by way of the PartneringONE® Platform.

About CENTOGENE

CENTOGENE (Nasdaq: CNTG) is remodeling real-world scientific, genetic, and multiomic knowledge to allow higher well being outcomes for sufferers with uncommon and neurodegenerative illnesses. For over 15 years, CENTOGENE has been offering diagnostic insights to sufferers with genetic illnesses by our community of almost 30,000 lively physicians. CENTOGENE now believes its Biodatabank is the world’s largest real-world knowledge repository of corresponding sufferers from greater than 120 international locations. Simplified logistics options, together with CentoCard® for sending biosamples, and our ISO, CAP, & CLIA licensed state-of-the-art multiomic reference labs provide sufferers speedy and dependable diagnoses to assist the identification and personalization of their remedies. Ultimately, providing one of the best remedy for sufferers includes creating new or higher therapies. We are de-risking orphan drug discovery and improvement by partnering with greater than 30 biopharma in goal & drug screening, scientific improvement, market entry and growth. CENTOGENE engages in biodata partnerships with our Biodata Licenses and Insight Reports.

See also  Blueberries Medical Announces Closing of US$1.1 Million

To uncover extra about our merchandise, pipeline, and patient-driven objective, go to www.centogene.com and comply with us on LinkedIn.

Forward-Looking Statements

This press launch accommodates “forward-looking statements” throughout the which means of the U.S. federal securities legal guidelines. Statements contained herein that aren’t clearly historic in nature are forward-looking, and the phrases “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and related expressions and future or conditional verbs akin to “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are typically meant to establish forward-looking statements. Such forward-looking statements contain identified and unknown dangers, uncertainties, and different essential components which will trigger CENTOGENE’s precise outcomes, efficiency, or achievements to be materially completely different from any future outcomes, efficiency, or achievements expressed or implied by the forward-looking statements. Such dangers and uncertainties embody, amongst others, unfavourable financial and geopolitical circumstances and instability and volatility in the worldwide monetary markets, potential modifications in present and proposed laws, rules and governmental insurance policies, pressures from growing competitors and consolidation in our trade, the expense and uncertainty of regulatory approval, together with from the U.S. Food and Drug Administration, our reliance on third events and collaboration companions, together with our skill to handle progress and enter into new consumer relationships, our dependency on the uncommon illness trade, our skill to handle worldwide growth, our reliance on key personnel, our reliance on mental property safety, fluctuations of our working outcomes due to the impact of change charges, our skill to streamline money utilization, our requirement for added financing, or different components. For additional data on the dangers and uncertainties that would trigger precise outcomes to differ from these expressed in these forward-looking statements, in addition to dangers relating to CENTOGENE’s business in basic, see CENTOGENE’s threat components set forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press launch converse solely as of the date hereof, and CENTOGENE’s particularly disclaims any obligation to replace any forward-looking assertion, whether or not on account of new data, future occasions, or in any other case.

See also  Open Book Extracts Receives Strategic Investment From Btomorrow Ventures As Lead Investor In Series C Financing

Media Contact:

CENTOGENE
Lennart Streibel 
Investor Relations 
Investor.Relations@centogene.com

Ben Legg 
Corporate Communications 
Press@centogene.com



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here